The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 17, 2023

Filed:

Sep. 23, 2019
Applicant:

The Brigham and Women's Hospital, Inc., Boston, MA (US);

Inventors:

Jesmond Dalli, Brookline, MA (US);

Nan Chiang, Somerville, MA (US);

Charles N. Serhan, Needham, MA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07C 59/42 (2006.01); A61K 31/202 (2006.01); A61P 31/04 (2006.01); A61K 31/40 (2006.01);
U.S. Cl.
CPC ...
C07C 59/42 (2013.01); A61K 31/202 (2013.01); A61K 31/40 (2013.01); A61P 31/04 (2018.01); Y02A 50/30 (2018.01);
Abstract

New host-protective molecules containing conjugated triene and diene double bonds with each carrying a 13-carbon position alcohol and were derived from n-3 docosapentaenoic acid (DPA, C22:5) were produced in neutrophil-endothelial co-cultures, and they are present in human and mouse tissues after sterile inflammation or infection. These compounds, termed 13-series resolvins (RvT), demonstrated potent protective actions increasing mice survival duringinfections. Their biosynthesis during neutrophil-endothelial cell interactions was initiated by endothelial cyclooxygenase-2 (COX-2) and increased by atorvastatin via S-nitrosylation of COX-2. Atorvastatin and RvT were additive ininfections in mice where they accelerated resolution of inflammation and increased survival >60%. Results documented novel host protective molecules in bacterial infections, namely RvT, derived from n-3 DPA via transcellular biosynthesis and increased by atorvastatin. RvT also regulated human and mouse phagocyte responses stimulating bacterial phagocytosis and regulating inflammasome components to regulate key innate protective responses in the resolution of infectious-inflammation.


Find Patent Forward Citations

Loading…